2 because of neurologic complications (seizure, stroke); This is a literature report. A health-care system experience. The full publication has been requested. This author reported different events for five patients. This is the third of five reports.  A subject of unspecified age and gender received bnt162b2 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as dose 1, single for COVID-19 immunisation. The medical history and concomitant medications were not reported. The subject experienced stroke on an unspecified date with outcome of unknown. The subject underwent lab tests and procedures which included allergy test with unknown results.  Background: Adverse reactions, including anaphylaxis, to messenger RNA coronavirus disease 2019 (COVID-19) vaccines rarely occur. Because of the need to administer a timely second dose in subjects who reported a reaction to their first dose, a panel of health-care professionals developed a safe triage of the employees and health care providers (HCP) at a large health-care system to consider administration of future dosing. Methods: There were 28,544 HCPs who received their first dose of COVID-19 vaccines between December 15, 2020, and March 8, 2021. The HCPs self-reported adverse reactions to a regulatory authority. A regulatory authority screened and collected information on the quality of reaction, symptoms, and timing of the onset of the reaction. Results: Of 1253 calls to a regulatory authority, 113 were identified as requiring consideration by a panel of three-certified allergists for future dosing or formal in-person assessment. Of the 113 EHCPs, 94 (83.2%) were recommended to get their second dose. Eighty of 94 received their second planned dose without a severe or immediate reaction. Of the 14 of 113 identified as needing further evaluation, 6 were evaluated by a physician and subsequently received their second dose without a serious adverse reaction. Eight of 14 did not receive their second dose. Only 5 of the 113 EHCPs reported reactions (4.4%) were recommended to not take the second dose: 3 (2.6%) because of symptoms consistent with anaphylaxis, and 2 because of neurologic complications (seizure, stroke). Conclusion: The panel demonstrated that, by consideration of reaction history alone, the ECHPs could be appropriately triaged to receive scheduled second dosing of COVID-19 vaccines without delays for in-person evaluation and allergy testing.; Sender's Comments: A contributory role of BNT162B2 in triggering the onset of the neurological complication presented as stroke might not be fully excluded, considering the plausible temporal relationship. More information such as medical history and demographic data are needed for fully meaningful assessment. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate,Linked Report(s) : US-PFIZER INC-202101300055 Same article/drug; Different patient/event